Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Immunogenetics|January 1, 1986
Genetic interaction between non-MHC T- and B-cell alloantigens in response to Rous sarcomas in chickensD G Gilmour, W M Collins, T L Fredericksen, et al.
Computers, Informatics, Nursing : CIN|December 17, 2011
Evaluation of a hands-free communication device in an acute care setting: a study of healthcare providers' perceptions of its performanceJill de Grood, Jean E Wallace, Steven P Friesen, et al.
The British Journal of Surgery|September 1, 1995
Insonation and impedance analysis in graft surveillanceK R Woodburn, A Murtagh, P Breslin, et al.
European Journal of Pain (London, England)|September 9, 2014
Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the ratR Wodarski, S Schuh-Hofer, D A Yurek, et al.
Journal of the Royal College of Surgeons of Edinburgh|February 1, 1990
Management of congenital arteriovenous malformationsA T Abdool-Carrim, R J Cuschieri, R Vohra, et al.
AJNR. American Journal of Neuroradiology|April 13, 2019
Increased Water Content in Periventricular Caps in Patients without Acute HydrocephalusT Sichtermann, J K Furtmann, S Dekeyzer, et al.
Pharmacology, Biochemistry, and Behavior|March 13, 2017
Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effectsJ M Witkin, J A Monn, J Li, et al.
Statistics in Medicine|September 5, 2024
Assessing the Performance of Machine Learning Methods Trained on Public Health Observational Data: A Case Study From COVID-19Davide Pigoli, Kieran Baker, Jobie Budd, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
Pageof 7